Elevance Health (NYSE:ELV) Updates FY 2025 Earnings Guidance

Elevance Health (NYSE:ELV) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 34.150-34.850 for the period, compared to the consensus EPS estimate of 34.580. The company issued revenue guidance of -.

Elevance Health Price Performance

ELV stock opened at $401.20 on Friday. Elevance Health has a 1 year low of $362.21 and a 1 year high of $567.26. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. The firm has a market capitalization of $93.05 billion, a PE ratio of 14.63, a price-to-earnings-growth ratio of 1.11 and a beta of 0.84. The business has a 50 day simple moving average of $386.32 and a 200-day simple moving average of $463.64.

Elevance Health (NYSE:ELV) last issued its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. Equities research analysts anticipate that Elevance Health will post 32.95 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be paid a dividend of $1.71 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a yield of 1.70%. Elevance Health’s payout ratio is 23.77%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Morgan Stanley cut their price target on shares of Elevance Health from $643.00 to $551.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Raymond James set a $485.00 target price on Elevance Health in a research report on Friday, October 18th. UBS Group lowered their price target on Elevance Health from $605.00 to $555.00 and set a “buy” rating for the company in a report on Friday, October 18th. StockNews.com upgraded shares of Elevance Health from a “hold” rating to a “buy” rating in a report on Friday, January 17th. Finally, Barclays dropped their price target on shares of Elevance Health from $622.00 to $501.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $524.87.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.